Breast cancer - PubMed (original) (raw)

Review

. 2017 Mar 18;389(10074):1134-1150.

doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17.

Affiliations

• PMID: 27865536
• DOI: 10.1016/S0140-6736(16)31891-8

Review

Breast cancer

Nadia Harbeck et al. Lancet. 2017.

Abstract

Breast cancer is one of the three most common cancers worldwide. Early breast cancer is considered potentially curable. Therapy has progressed substantially over the past years with a reduction in therapy intensity, both for locoregional and systemic therapy; avoiding overtreatment but also undertreatment has become a major focus. Therapy concepts follow a curative intent and need to be decided in a multidisciplinary setting, taking molecular subtype and locoregional tumour load into account. Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early breast cancer, neoadjuvant therapy has become a commonly used option. Depending on clinical tumour subtype, therapeutic backbones include endocrine therapy, anti-HER2 targeting, and chemotherapy. In metastatic breast cancer, therapy goals are prolongation of survival and maintaining quality of life. Advances in endocrine therapies and combinations, as well as targeting of HER2, and the promise of newer targeted therapies make the prospect of long-term disease control in metastatic breast cancer an increasing reality.

Copyright © 2017 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Similar articles

• The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
  Yang TJ, Morrow M, Modi S, Zhang Z, Krause K, Siu C, McCormick B, Powell SN, Ho AY. Yang TJ, et al. Ann Surg Oncol. 2015 Dec;22 Suppl 3(Suppl 3):S495-501. doi: 10.1245/s10434-015-4697-7. Epub 2015 Jul 1. Ann Surg Oncol. 2015. PMID: 26130454 Free PMC article.
• The curability of breast cancer and the treatment of advanced disease.
  Guarneri V, Conte PF. Guarneri V, et al. Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. doi: 10.1007/s00259-004-1538-5. Epub 2004 Apr 24. Eur J Nucl Med Mol Imaging. 2004. PMID: 15107948 Review.
• Impact of breast cancer subtypes and patterns of metastasis on outcome.
  Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P. Kast K, et al. Breast Cancer Res Treat. 2015 Apr;150(3):621-9. doi: 10.1007/s10549-015-3341-3. Epub 2015 Mar 18. Breast Cancer Res Treat. 2015. PMID: 25783184
• Breast cancer.
  Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Harbeck N, et al. Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Nat Rev Dis Primers. 2019. PMID: 31548545 Review.
• Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
  Harbeck N. Harbeck N. Breast. 2015 Nov;24 Suppl 2:S44-8. doi: 10.1016/j.breast.2015.07.011. Epub 2015 Aug 25. Breast. 2015. PMID: 26321480

Cited by

• Retrospective study of the factors involved in the development of adenomyosis and the in vitro link between adenomyosis and breast cancer.
  Borozan F, Semenescu AD, Sas I, Bernad E, Iftode A, Iftode C, Susan M, Radu D. Borozan F, et al. Med Pharm Rep. 2024 Oct;97(4):477-487. doi: 10.15386/mpr-2747. Epub 2024 Oct 30. Med Pharm Rep. 2024. PMID: 39502755 Free PMC article.
• The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay.
  Jun E, Park Y, Lee W, Kwon J, Lee S, Kim MB, Lee JS, Song KB, Hwang DW, Lee JH, Hoffman RM, Kim SC. Jun E, et al. Sci Rep. 2020 Jul 20;10(1):12004. doi: 10.1038/s41598-020-68703-x. Sci Rep. 2020. PMID: 32686712 Free PMC article.
• Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study.
  Yang JR, Kuo WL, Yu CC, Chen SC, Huang JJ. Yang JR, et al. BMC Cancer. 2021 May 8;21(1):522. doi: 10.1186/s12885-021-08256-y. BMC Cancer. 2021. PMID: 33964927 Free PMC article.
• ZNF367-induced transcriptional activation of KIF15 accelerates the progression of breast cancer.
  Zeng H, Li T, Zhai D, Bi J, Kuang X, Lu S, Shan Z, Lin Y. Zeng H, et al. Int J Biol Sci. 2020 May 16;16(12):2084-2093. doi: 10.7150/ijbs.44204. eCollection 2020. Int J Biol Sci. 2020. PMID: 32549756 Free PMC article.
• Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
  Abahssain H, Souadka A, Alem R, Santoni M, Battelli N, Amela E, Lemaire A, Rodriguez J, Errihani H. Abahssain H, et al. Curr Oncol. 2024 Jun 30;31(7):3771-3782. doi: 10.3390/curroncol31070278. Curr Oncol. 2024. PMID: 39057150 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal